Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Shimadzu Corporation    7701   JP3357200009

SHIMADZU CORPORATION (7701)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Shimadzu Corporation : New Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Evaluation of 100 nm to 10 µm SVP (sub-visible particle) Aggregates

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/11/2013 | 09:19am CEST
Press Release
07/11/13
New Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Evaluation of 100 nm to 10 µm SVP (sub-visible particle) Aggregates

Shimadzu Corporation released the Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals on July 10.

The Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals offers quantitative, high-speed evaluation of 100 nm to 10 µm SVP (sub-visible particle) aggregates that may be present in biopharmaceuticals. Capable of evaluating the concentration (µg/mL) of aggregates that can cause shock symptom or other side effects, it is ideally suited for quality control and for improving the efficiency of biopharmaceutical development.

Background to Development

Biopharmaceuticals are essential to modern medicine, accounting for four of the top five products in 2012 drug sales, and the market is expected to reach $ 210 billion by 2015*. However, the generation of SVP aggregates in the sub-visible range due to mechanical stimulation or temperature changes, and the severe side effects that this induces, such as anaphylaxis (allergic systemic reactions), are concerning. Until now, no effective SVP aggregate analysis technique has been established. Shimadzu's new system significantly reduces costs and development times by allowing samples to be evaluated for aggregation at the early stages of biopharmaceutical development. In addition, it allows aggregation-prone proteins to be screened and eliminated in advance.

* Source: Cedium strategic data site

Features of the New Product 1. Quantitatively evaluates SVP range aggregate concentrations

The Aggregates Sizer measures aggregates of a wide range of particles sizes, from 7 nm to 800 µm, as part of a particle size distribution (displayed with particle quantities totaling 100 %). Furthermore, it enables quantitative evaluation (in terms of µg/mL) of aggregate concentrations in the SVP (sub-visible particle) range, from 100 nm to 10 µm.

2. Measures aggregates with sensitivity 10 times higher than previous particle size analyzers

The Aggregates Sizer is over ten times more sensitive than Shimadzu's previous SALD series particle size analyzers. This means that even micro sample quantities can be measured accurately using disposable cells for 0.4 mL sample quantities.

3. Quantitatively evaluates aggregation processes at intervals as short as one second

Changes (sizes and quantities) in aggregates can be confirmed quantitatively as a concentration (unit: µg/mL) at intervals as short as one second. This allows observing the status at various intermediate stages in order to evaluate rates of change. In addition, a batch cell (5 mL sample capacity) enables observation of aggregation processes as samples are mechanically stimulated.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SHIMADZU CORPORATION
06/22SHIMADZU : Patent Issued for Mass Analyser and Method of Mass Analysis (USPTO 99..
AQ
06/22SHIMADZU : partners with Protein Metrics to provide advanced solutions for bioth..
AQ
06/22SHIMADZU : Patent Issued for Material Testing Machine That Properly Performs a T..
AQ
06/22SHIMADZU : Patent Issued for Flow Cell (USPTO 9995673)
AQ
06/21SHIMADZU : "X-Ray Fluoroscopic Apparatus" in Patent Application Approval Process..
AQ
06/21SHIMADZU : partners with Protein Metrics to provide advanced solutions for bioth..
AQ
06/21SHIMADZU CORPORATION : collaborates with PREMIER Biosoft to launch a comprehensi..
AQ
06/20SHIMADZU CORPORATION : collaborates with PREMIER Biosoft to launch a comprehensi..
AQ
06/19SHIMADZU : enhances its Mass Spectrometry Platform with the launch of a new Q-TO..
AQ
06/14SHIMADZU : Patent Issued for Simultaneous Multicompound Analysis Method and Simu..
AQ
More news
News from SeekingAlpha
2017FDA OKs first seven tesla MRI system in U.S. 
Financials ( JPY)
Sales 2019 395 B
EBIT 2019 -
Net income 2019 33 851 M
Finance 2019 66 077 M
Yield 2019 0,84%
P/E ratio 2019 28,17
P/E ratio 2020 25,32
EV / Sales 2019 2,27x
EV / Sales 2020 2,12x
Capitalization 961 B
Chart SHIMADZU CORPORATION
Duration : Period :
Shimadzu Corporation Technical Analysis Chart | 7701 | JP3357200009 | 4-Traders
Technical analysis trends SHIMADZU CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 3 488  JPY
Spread / Average Target 7,5%
EPS Revisions
Managers
NameTitle
Teruhisa Ueda Executive President, CEO & Representative Director
Akira Nakamoto Executive Chairman
Yasunori Yamamoto Head-Information Systems & Manufacturing
Hiroshi Fujino Director & Senior Managing Executive Officer
Yasuo Miura Director, Head-Sales & Accounting
Sector and Competitors
1st jan.Capitalization (M$)
SHIMADZU CORPORATION24.62%8 732
SMC CORP-9.96%26 024
METTLER-TOLEDO INTERNATIONAL-6.01%14 787
KEYSIGHT TECHNOLOGIES INC44.47%11 271
COGNEX CORPORATION-26.24%7 802
MKS INSTRUMENTS, INC.4.87%5 419